Singapore-based molecular diagnostics firms Nova Satra Dx (Nova Satra) and INEX Innovations Exchange (INEX) have merged to create a $72-million entity that eyes a possible IPO in 2021.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
